Search

Learn what to do right after you've been diagnosed with colorectal cancer, from an MSK expert who specializes in treating this kind of cancer.

… Wednesday, February 25, 2026 They are four words that can make your world stop: “You have colorectal cancer.”  After the shock wears off, many people ask themselves, “What do I do now?”  They wonder: “Who should I trust with treatment? What options do I have for therapy? How will cancer affect my family

Cancer among younger Americans is on the rise, and much of it is linked to obesity. An MSK expert on diet and cancer explains what’s behind this disturbing new trend.

… Thursday, May 30, 2019 Summary Research has found that the incidence of several cancers is on the rise among younger adults in the United States. An MSK expert on diet and cancer explains how the obesity epidemic is to blame. There is a lot to celebrate in the battle against cancer. Research by the American

Memorial Sloan Kettering researchers have discovered a way that cancer cells may be able to exchange information by establishing long bridges between cells called tunneling nanotubes.

… Wednesday, September 19, 2012 Summary Memorial Sloan Kettering researchers have discovered a way that cancer cells may be able to exchange information by establishing long bridges between cells called tunneling nanotubes. Memorial Sloan Kettering researchers have discovered a way that cancer cells may

A phase 2 randomized clinical trial at MSK has found that acupuncture can improve cognitive abilities in breast cancer survivors experiencing "brain fog."

… Friday, December 12, 2025 Cancer-related cognitive impairment — often called “brain fog” or “chemo brain” — has been shown to affect about 40% of breast cancer survivors, making it difficult for them to focus, work, and perform daily tasks.  But acupuncture may help alleviate this brain fog, according

As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.

… Friday, October 1, 2010 Summary As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials. As part of a commitment

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings were published today online in the British Medical Journal.

… Tuesday, September 14, 2010 A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online

Six students have successfully defended their dissertations and will receive their PhD degrees at Commencement on May 10.

… Monday, April 29, 2013 Six students at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences have successfully defended their dissertations. As part of Memorial Sloan Kettering’s 34th annual academic convocation on May 10, the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences

Dr. Nai-Kong V. Cheung, MD, PhD, the Enid A. Haupt Chair in Pediatric Oncology at MSK, was honored by the Advances in Neuroblastoma Research Association (ANRA) with its 2025 lifetime achievement award. An esteemed physician-scientist, Dr. Cheung leads a laboratory in Memorial Hospital Research Laboratories at MSK, which is focused on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

… Thursday, July 17, 2025 Dr. Nai-Kong V. Cheung, MD, PhD, the Enid A. Haupt Chair in Pediatric Oncology at MSK, was honored by the Advances in Neuroblastoma Research Association (ANRA) with its 2025 lifetime achievement award. An esteemed physician-scientist, Dr. Cheung leads a laboratory in Memorial

Computer models suggest breast cancer screening guidelines for people with mutations in the genes ATM, CHEK2, and PALB2.

… Thursday, February 17, 2022 Many people have heard of mutations in the BRCA1 and BRCA2 genes that are linked to an increased risk of certain cancers, including breast cancer . But there are other, less well-known genes in which hereditary mutations can also increase breast cancer risk, including ATM

MSK chemists are focusing on developing small-molecule drugs to target KRas, an important cancer protein.

… Wednesday, May 24, 2017 Summary MSK chemists are focusing on developing small-molecule drugs to target KRas, an important cancer protein. KRas is linked to nearly 30% of all cancers. Drug development is a complicated task. In the era of targeted therapies for cancer, medicinal chemists seek to design